Oracle Alpha’s NovoCure NVCR Stock Holding History

Oracle Alpha’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$240K	Buy	15,367 +2,600	+20%	+$38.2K	0.43%	121
2023 Q4	$191K	Buy	+12,767	New	+$171K	0.25%	195

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Alpha's NVCR Position: Q1 2024 in Review

Oracle Alpha increased its NovoCure (NVCR) stake by 20% in Q1 2024, buying an estimated $38.2K and bringing the position to 15,367 shares worth $240K. The position accounts for 0.43% of the portfolio, ranked #121.

Oracle Alpha first reported a position in NVCR in Q4 2023 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Oracle Alpha held 15,367 shares of NovoCure worth $240K as of Q1 2024.
Oracle Alpha bought 2,600 NovoCure shares in Q1 2024, an estimated $38.2K.
NovoCure made up 0.43% of Oracle Alpha's portfolio in Q1 2024, its #121 holding.
Oracle Alpha first reported a position in NovoCure in Q4 2023 and has held it in 2 quarters since.
238 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.